NCT05101356View on ClinicalTrials.gov

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

October 13, 2021

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2030

Conditions
Advanced AdenocarcinomaAdvanced Malignant Solid NeoplasmMetastatic AdenocarcinomaMetastatic Malignant Solid NeoplasmRecurrent AdenocarcinomaRecurrent Malignant Solid Neoplasm
Interventions
BIOLOGICAL

Antineoplastic Vaccine

Given LabVax 3(22)-23 ID

BIOLOGICAL

Sargramostim

Given SC

BIOLOGICAL

Pembrolizumab

Given IV per standard of care

Trial Locations (1)

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

LabyRx Immunologic Therapeutics

UNKNOWN

lead

Tianhong Li

OTHER